<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00336765</url>
  </required_header>
  <id_info>
    <org_study_id>XL647-002</org_study_id>
    <nct_id>NCT00336765</nct_id>
  </id_info>
  <brief_title>Study of XL647 Administered Orally Daily to Patients With Solid Tumors</brief_title>
  <official_title>A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL647 Administered Orally Daily to Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kadmon Corporation, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kadmon Corporation, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of the multiple receptor
      tyrosine kinase (RTK) inhibitor (including EGFR, VEGFR2, ErbB2, and EphB4) XL647 when given
      orally daily to adults with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate safety, tolerability, and maximum tolerated dose of XL647</measure>
    <time_frame>Inclusion until 30 days post last treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize pharmacokinetics and pharmacodynamic effects of XL647</measure>
    <time_frame>At various time points from pre-dosing until post dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary tumor response</measure>
    <time_frame>Inclusion until disease progression</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XL647</intervention_name>
    <description>Tablets supplied in 50-mg strength administered orally daily</description>
    <other_name>KD019</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has histologically confirmed malignancy that is metastatic or unresectable

          -  Subject has disease that is assessable by tumor marker, physical, or radiologic means

          -  Subject is at least 18 years old

          -  Subject has an ECOG performance status ≤ 2 (Karnofsky ≥ 60%)

          -  Subject has a life expectancy ≥ 3 months

          -  Subject has normal organ and marrow function

          -  Subject gives written informed consent

          -  Subject must use an accepted method of contraception during the study

          -  Female subjects of childbearing potential must have a negative pregnancy test

        Exclusion Criteria:

          -  Subject has received anticancer treatment within 30 days of first dose of XL647

          -  Subject has received another investigational agent within 30 days of first dose of
             XL647

          -  Subject has known brain metastases

          -  Subject has corrected QT interval (QTc) of &gt; 0.45 seconds

          -  Subject is currently receiving anticoagulation therapy with warfarin

          -  Subject has uncontrolled intercurrent illness

          -  Subject is pregnant or breastfeeding

          -  Subject has known HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2006</study_first_submitted>
  <study_first_submitted_qc>June 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2006</study_first_posted>
  <last_update_submitted>October 17, 2011</last_update_submitted>
  <last_update_submitted_qc>October 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumors</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

